The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure

被引:65
作者
Kotlyar, E
Vita, JA
Winter, MR
Awtry, EH
Siwik, DA
Keaney, JF
Sawyer, DB
Cupples, LA
Colucci, WS
Sam, F
机构
[1] Boston Univ, Evans Dept Med, Cardiovasc Med Sect, Boston, MA 02215 USA
[2] Boston Univ, Evans Dept Med, Myocardial Biol Unit, Boston, MA USA
[3] Boston Univ, Sch Publ Hlth, Boston, MA USA
关键词
aldosterone; oxidative stress; inflammation; matrix; heart failure;
D O I
10.1016/j.cardfail.2005.08.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Aldosterone antagonists reduce morbidity and mortality in patients with severe heart failure, but the mechanisms responsible are not fully understood. Observations in animal models suggest that elevated levels of aldosterone promote oxidative stress and inflammation in the myocardium. It is unknown if these findings are relevant to heart failure patients who may have much lower aldosterone levels. Methods and Results: We therefore examined the relationship of plasma aldosterone levels to markers of oxidative stress, inflammation and matrix turnover in 58 patients with chronic, stable heart failure from systolic dysfunction (LV ejection fraction < 0.40) who were not receiving aldosterone antagonists. Chronic, stable heart failure patients had modestly elevated levels of aldosterone. Additionally, these patients had elevated levels of 8-isoprostaglandin F-2 alpha, C-reactive protein, soluble intercellular adhesion molecule-1, osteopontin, brain natriuretic peptide, procollagen type III aminoterminal peptide, and tissue inhibitor of metalloproteinase-1. Among these patients with heart failure, aldosterone levels correlated with 8-iso-PGF(2 alpha) (P = .003), ICAM-1 (P = .008), and TIMP-1 (P = .006) after adjustment for age, gender, race, diabetes, smoking, heart rate, left ventricular mass, and body mass index. Conclusion: In chronic, stable heart failure patients on standard therapy, higher aldosterone levels are associated with systemic evidence of oxidative stress, inflammation, and matrix turnover.
引用
收藏
页码:122 / 127
页数:6
相关论文
共 48 条
[11]   ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT-VENTRICULAR HYPERTROPHY - COMPARISON TO NECROPSY FINDINGS [J].
DEVEREUX, RB ;
ALONSO, DR ;
LUTAS, EM ;
GOTTLIEB, GJ ;
CAMPO, E ;
SACHS, I ;
REICHEK, N .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (06) :450-458
[12]   Modulation of the inflammatory response in cardiovascular disease [J].
Granger, DN ;
Vowinkel, T ;
Petnehazy, T .
HYPERTENSION, 2004, 43 (05) :924-931
[13]   SUPEROXIDE ANION IS INVOLVED IN THE BREAKDOWN OF ENDOTHELIUM-DERIVED VASCULAR RELAXING FACTOR [J].
GRYGLEWSKI, RJ ;
PALMER, RMJ ;
MONCADA, S .
NATURE, 1986, 320 (6061) :454-456
[14]   Systemic inflammation in patients with heart failure [J].
Hasper, D ;
Hummel, M ;
Kleber, FX ;
Reindl, I ;
Volk, HD .
EUROPEAN HEART JOURNAL, 1998, 19 (05) :761-765
[15]   Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease - Possible role for left ventricular remodelling [J].
Kameda, K ;
Matsunaga, T ;
Abe, N ;
Hanada, H ;
Ishizaka, H ;
Ono, H ;
Saitoh, M ;
Fukui, K ;
Fukuda, K ;
Osanai, T ;
Okumura, K .
EUROPEAN HEART JOURNAL, 2003, 24 (24) :2180-2185
[16]   Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload [J].
Kuster, GM ;
Kotlyar, E ;
Rude, MK ;
Siwik, DA ;
Liao, RL ;
Colucci, WS ;
Sam, F .
CIRCULATION, 2005, 111 (04) :420-427
[17]   H2O2 regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways [J].
Kwon, SH ;
Pimentel, DR ;
Remondino, A ;
Sawyer, DB ;
Colucci, WS .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (06) :615-621
[18]   Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension [J].
Laursen, JB ;
Rajagopalan, S ;
Galis, Z ;
Tarpey, M ;
Freeman, BA ;
Harrison, DG .
CIRCULATION, 1997, 95 (03) :588-593
[19]   TIMP-1 - A marker of left ventricular diastolic dysfunction and fibrosis in hypertension [J].
Lindsay, MM ;
Maxwell, P ;
Dunn, FG .
HYPERTENSION, 2002, 40 (02) :136-141
[20]  
Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719